Callan Capital LLC Boosts Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Callan Capital LLC boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,950 shares of the company’s stock after acquiring an additional 1,750 shares during the quarter. Callan Capital LLC owned 0.05% of Tarsus Pharmaceuticals worth $343,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of TARS. Deerfield Management Company L.P. Series C purchased a new stake in Tarsus Pharmaceuticals during the third quarter valued at $13,399,000. Artisan Partners Limited Partnership bought a new stake in Tarsus Pharmaceuticals during the third quarter valued at about $7,093,000. RTW Investments LP grew its holdings in Tarsus Pharmaceuticals by 13.1% during the third quarter. RTW Investments LP now owns 2,880,701 shares of the company’s stock valued at $51,190,000 after purchasing an additional 332,576 shares during the period. Vanguard Group Inc. grew its holdings in Tarsus Pharmaceuticals by 25.6% during the third quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company’s stock valued at $27,576,000 after purchasing an additional 316,128 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Tarsus Pharmaceuticals during the third quarter valued at about $4,339,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 0.5 %

Shares of Tarsus Pharmaceuticals stock traded down $0.17 during trading on Friday, reaching $32.04. The company’s stock had a trading volume of 373,901 shares, compared to its average volume of 717,980. The company has a quick ratio of 6.85, a current ratio of 6.93 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -6.91 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a 1-year low of $12.57 and a 1-year high of $40.40. The company has a 50-day simple moving average of $34.02 and a two-hundred day simple moving average of $24.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The firm had revenue of $13.08 million during the quarter, compared to analysts’ expectations of $4.63 million. During the same quarter last year, the business earned ($0.49) EPS. As a group, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.25 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Bryan Wahl sold 4,436 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the transaction, the general counsel now owns 40,951 shares in the company, valued at approximately $1,253,100.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,415 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $30.60, for a total transaction of $318,699.00. Following the completion of the transaction, the chief executive officer now owns 26,456 shares in the company, valued at approximately $809,553.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Bryan Wahl sold 4,436 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the transaction, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The disclosure for this sale can be found here. Insiders sold 24,496 shares of company stock worth $749,578 in the last 90 days. Insiders own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on TARS. HC Wainwright boosted their price target on Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Barclays boosted their price target on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. Jefferies Financial Group upped their price objective on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a research note on Thursday, February 29th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 price objective (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.38.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.